Sales Performance - The sales of growth hormone have maintained steady growth in Q1 2025, with ongoing academic promotion efforts aimed at achieving recovery growth [1] - The sales revenue of Trastuzumab exceeded 100 million CNY in 2024, with a continuous upward trend since its launch, and significant growth expected in 2025 [1] Clinical Development - The HuA21 injection, targeting HER2, has completed the enrollment of subjects for Phase Ib/II clinical studies and plans to initiate Phase III trials based on mid-term analysis results [2] - The company is actively constructing production lines compliant with FDA and EU certifications, with ongoing validation and data organization for international market commercialization [2] mRNA Drug Development - The company is collaborating with Hefei Afana to develop mRNA drugs, specifically the AFN0328 injection for treating HPV-related cancers, currently in Phase I clinical trials [2] Oncolytic Virus Therapy - The company’s partner, Yuansong Biotech, has received clinical trial approval for the recombinant L-IFN adenovirus injection (YSCH-01), which is currently undergoing Phase I-IIa trials for advanced solid tumors [4]

Group 1: Company Overview and Investor Relations - The investor relations activity included a site visit to the company's exhibition hall and production lines, followed by a Q&A session with investors [2] - The company is engaged in the production of growth hormones using recombinant E. coli technology, with a composition of 191 amino acids identical to human growth hormone [2] Group 2: Growth Hormone Mechanism and Competitive Landscape - Growth hormone plays a crucial role in human growth, development, and metabolic regulation, with peak secretion during deep sleep [2] - There are currently 5 companies producing short-acting growth hormone, and 2 companies with long-acting growth hormone, with a strategic partnership expected to yield long-acting growth hormone approval in the second half of 2025 [3] Group 3: Competitive Advantages - The company leverages technological and industrial advantages, talent, and production capabilities to innovate and enhance product competitiveness [3] - The marketing strategy focuses on deepening market segmentation, optimizing promotion strategies, and strengthening brand building, covering over 4,000 large and medium-sized hospitals nationwide [3] - The company pursues strategic investments in high-tech pharmaceutical companies to enhance core competitiveness and risk resilience [3] Group 4: Technological Advancements - The company has received clinical approval for the CAR-Vδ1T cell therapy (UTAA09 injection), marking a global first in this category [4] - Collaboration with Hefei Afana Company on mRNA drugs has led to the clinical approval of AFN0328 injection for HPV tumors, currently in Phase I trials [4] - The company is also developing oncolytic virus drugs, with a product receiving clinical trial approval for late-stage solid tumors [4] Group 5: AI Integration in Drug Development - The company utilizes AI technologies to assist in drug development, reducing time and costs, and has already seen clinical approvals for drugs developed using AI platforms [5] - AI applications are being expanded across various business scenarios, including patient management and marketing data analysis [5] Group 6: Clinical Pipeline Overview - The company has several ongoing clinical trials, including: - HuA21 injection for HER2-targeted therapy, currently in Phase III trials [6] - AK2017 injection (recombinant human growth hormone) progressing to Phase III trials [7] - AK1008 and AK1012 projects for treating viral infections in children, in Phase II and I trials respectively [7] - Development of regulatory T cell therapies for autoimmune diseases, with clinical trials initiated [7]

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

Core Viewpoint - Anke Biotech aims for restorative growth in 2025, focusing on enhancing sales of water injections and promoting the recovery of growth hormone sales while optimizing its traditional Chinese medicine segment and expanding its peptide and chemical drug markets [2][4][5]. Business Strategy - The company plans to strengthen academic promotion and increase the sales proportion of water injections, while also pushing for the recovery of growth hormone sales [2]. - The traditional Chinese medicine segment has resumed production since December 2024, with efforts to optimize sales policies and maintain growth in traditional Chinese medicine [2]. - The peptide segment will focus on market analysis and expanding the sales scale of raw materials for enterprises that win centralized procurement bids [2]. - The company intends to divest its forensic-related business and actively transition to new business areas [2]. Investment Activities - Anke Biotech has made cornerstone investments in Weisheng Pharmaceutical, aiming to establish a long-term cooperative relationship and enhance strategic collaboration to improve risk resistance and core competitiveness [3]. Sales Performance - In Q1 2025, the company reported a year-on-year increase in new patients for growth hormone, reversing a previous decline, with shipping showing an upward trend [4]. - The product Trastuzumab is in a rapid market introduction phase, with sales exceeding 100 million yuan in 2024 and expected significant year-on-year growth in 2025 [5]. Research and Development - The company is advancing several clinical trials, including Hu1 injection for HER2 targets, which has shown promising safety and efficacy in early studies [6]. - The recombinant anti-VEGF humanized monoclonal antibody has completed phase III clinical trials, and the company is working on its market application [6]. - The company is also developing innovative drugs targeting HER2 and has submitted IND applications for several projects [6]. Financial Overview - In Q1 2025, Anke Biotech reported a main revenue of 629 million yuan, a year-on-year decrease of 4.17%, and a net profit of 209 million yuan, also down 4.02% [8]. - The company has a debt ratio of 16.52% and a gross profit margin of 76.96% [8]. - Recent institutional ratings indicate a buy recommendation from two firms, with a target average price of 10.08 yuan [8].

Group 1: Company Goals and Strategies - The overall business goal for 2025 is to achieve restorative growth while maintaining stable and healthy development [2] - The company aims to enhance academic promotion and increase the sales proportion of water injections, while pushing for restorative growth in growth hormone sales [2] - The Chinese medicine sector will optimize sales policies for traditional Chinese medicine plasters to maintain growth momentum [2] Group 2: Investment and Partnerships - The cornerstone investment in Weisheng Pharmaceutical is aimed at establishing a long-term cooperative relationship to enhance resource integration and competitive advantage [3] - The company plans to divest forensic-related businesses and actively transition to new business areas [3] Group 3: Sales Performance - In Q1 2025, the sales of growth hormones showed a year-on-year increase, reversing the previous downward trend [3] - The sales revenue of Trastuzumab exceeded 100 million yuan in 2024, with expectations for significant year-on-year growth in 2025 [3] Group 4: Research and Development Progress - The company is advancing several clinical trials, including a new drug targeting HER2, which has shown promising safety and efficacy in early studies [4] - Ongoing clinical trials for various products, including AK1008 and AK1012, are aimed at treating viral infections in children [4] - The company is collaborating on innovative mRNA technology for cancer treatment, with clinical trials approved for AFN0328 injection [4]

Core Viewpoint - The leading companies in the growth hormone sector, Changchun High-tech and Anke Bio, are facing declining revenues and are seeking new growth avenues through diversification into other therapeutic areas [1][2][3]. Group 1: Company Performance - Both Changchun High-tech and Anke Bio reported a decline in revenue and net profit for 2024, with Changchun High-tech experiencing its first annual revenue drop in nearly 20 years, showing a 5.66% decrease in revenue and a 44.95% drop in net profit for Q1 2025 [2][3]. - Anke Bio's revenue and net profit also fell by over 10% in the previous year, with a 4% decline in both metrics for Q1 2025 [2][3]. Group 2: Market Dynamics - The growth hormone market in China has expanded significantly, from $600 million in 2018 to $1.7 billion in 2022, capturing 34% of the global market share, surpassing the United States [2]. - The introduction of price-cutting measures in 2022 has pressured the revenues of the two leading companies, leading to a contraction in their growth hormone business [2][3]. Group 3: Product Development and Diversification - Changchun High-tech and Anke Bio are both attempting to diversify their product lines beyond growth hormones, with Changchun High-tech planning to expand into pediatrics, women's health, and anti-aging sectors [4][5]. - Changchun High-tech's subsidiary, GenSci, has seen over 76% of its revenue coming from growth hormones, while Anke Bio's growth hormone sales account for nearly 70% of its total revenue [3]. - Both companies have initiated clinical trials for new products, with Changchun High-tech focusing on innovative drugs and Anke Bio expanding into antiviral and oncology treatments [5].

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

证券代码：300009 证券简称：安科生物 公告编号：2025-030 安徽安科生物工程（集团）股份有限公司 关于醋酸阿托西班注射液获批上市的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 近日，安徽安科生物工程（集团）股份有限公司（以下简称"公司"）收到国 家药品监督管理局签发的醋酸阿托西班注射液《药品注册证书》。现将具体情况公 告如下： 一、药品的基本情况 药品名称：醋酸阿托西班注射液 剂型：注射剂 注册分类：化学药品 4 类 药品批准文号：国药准字 H20254203、国药准字 H20254204 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、产品用途及特点 阿托西班是一种选择性缩宫素受体拮抗剂，可以竞争性结合子宫肌层缩宫素受 体，在受体水平上抑制由缩宫素导致的子宫收缩，达到治疗早产的目的；其适用于 有下列情况的妊娠妇女，以推迟即将来临的早产： 1、每次至少 30 秒的规律子宫收缩，每 30 分钟内≥4 次； 2、宫颈扩张 1-3cm（未经产妇 0~3cm）和子宫软化度/变 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-029 安徽安科生物工程（集团）股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 特别提示： 指引第9号——回购股份》等相关规定，通过回购专用证券账户持有的本公司股份不享有 利润分配的权利。安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 2024 年年度权益分派将以1,668,333,852股为基数，向全体股东按每10股派发现金股利1.5元（含 税），共计派发现金股利250,250,077.80元。 价计算如下： 本次除权前公司总股本为1,672,521,258股，其中公司回购专用账户中回购股份不参与 分红。本次权益分派实施后，按总股本折算每10股现金分红比例=（本次实际现金分红总 额（含税）/公司总股本）*10=（250,250,077.80元/1,672,521,258股）*10 =1.496244元（保 留到小数点后六位，最后一位直接截取，不四舍五入）。 在保证本次权益分派方案不变的前提下，2024年年度权益分派实施后的除权除息价 格按照上述原则及计算方式执行，即本次权益分 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-029 安徽安科生物工程（集团）股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 特别提示： 1、本次权益分派的分配基数：根据《公司法》《深圳证券交易所上市公司自律监管 指引第9号——回购股份》等相关规定，通过回购专用证券账户持有的本公司股份不享有 利润分配的权利。安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 2024 年年度权益分派将以1,668,333,852股为基数，向全体股东按每10股派发现金股利1.5元（含 税），共计派发现金股利250,250,077.80元。 2、本次权益分派实施后，按公司总股本折算每10股现金分红比例以及除权除息参考 价计算如下： 本次除权前公司总股本为1,672,521,258股，其中公司回购专用账户中回购股份不参与 分红。本次权益分派实施后，按总股本折算每10股现金分红比例=（本次实际现金分红总 额（含税）/公司总股本）*10=（250,250,077.80元/1,672,521,258股）*10 =1.496 ...